{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:03:08Z","timestamp":1788242588032,"version":"build-2803163510"},"reference-count":0,"publisher":"Academy of Medicine, Singapore","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Acad Med Singap"],"abstract":"<jats:p>Introduction: Trastuzumab deruxtecan (T-DXd) has revolutionised treatment for metastatic breast cancer (MBC). While effective, its high cost and toxicities, such as fatigue and nausea, pose challenges. \n\nMethod: Medical records from the Joint Breast Cancer Registry in Singapore were used to study MBC patients treated with T-DXd (February 2021\u2013June 2024). This study was conducted to address whether reducing dose intensity and density may have an adverse effect on treatment outcomes. \n\nResults: Eighty-seven MBC patients were treated with T-DXd, with a median age of 59 years. At the time of data cutoff, 32.1% of patients were still receiving T-DXd. Over half (54%) of the patients received treatment with an initial relative dose intensity (RDI) of \u226585%. Overall median real-world progression-free survival (rwPFS) was 8.1 months. rwPFS was similar between RDI groups (&lt;85%: 8.7 months, \u226585%: 8.1 months, P=0.62). However, human epidermal growth receptor 2 (HER2)-positive patients showed significantly better rwPFS outcomes compared to HER2-low patients (8.8 versus 2.5 months, P&lt;0.001). Only 16% with central nervous system (CNS) involvement had CNS progressive disease on treatment. No significant progression-free survival (PFS) differences were found between patients with or without CNS disease, regardless of RDI groups. Five patients (5.7%) developed interstitial lung disease (ILD), with 3 (3.4%) having grade 3 events. Two required high-dose steroids and none were rechallenged after ILD. There were no fatalities. \n\nConclusion: Our study demonstrated that reduced dose intensity and density had no significant impact on rwPFS or treatment-related toxicities. Furthermore, only 5.7% of patients developed ILD. T-Dxd provided good control of CNS disease, with 82% of patients achieving CNS disease control.<\/jats:p>","DOI":"10.47102\/annals-acadmedsg.202576","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T05:50:26Z","timestamp":1754459426000},"page":"458","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting"],"prefix":"10.47102","volume":"54","author":[{"given":"Han Yi","family":"Lee","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne","family":"Shih","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7214-8368","authenticated-orcid":false,"given":"Jack Junjie","family":"Chan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun Zi","family":"Liong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Shea Ying Cong","family":"Tan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Ji Guang","family":"Chua","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Zhi Chien","family":"Tan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan Yaw","family":"Lee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Ling","family":"Teo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Ming","family":"Tan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02q854y08","id-type":"ROR","asserted-by":"publisher"}],"name":"Changi General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyu","family":"Nitar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02q854y08","id-type":"ROR","asserted-by":"publisher"}],"name":"Changi General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Sim","family":"Yap","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Wong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Dent","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-3371","authenticated-orcid":false,"given":"Fuh Yong","family":"Wong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5329-7192","authenticated-orcid":false,"given":"Tira J","family":"Tan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26165","published-online":{"date-parts":[[2025,8,6]]},"container-title":["Annals of the Academy of Medicine, Singapore"],"original-title":[],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:56:47Z","timestamp":1756450607000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals.edu.sg\/evaluating-the-impact-of-relative-dose-intensity-on-efficacy-of-trastuzumab-deruxtecan-for-metastatic-breast-cancer-in-the-real-world-clinical-setting\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":0,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.47102\/annals-acadmedsg.202576","relation":{},"ISSN":["2972-4066"],"issn-type":[{"value":"2972-4066","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}